Daiichi Sankyo's edoxaban shows Phase III promise in orthopaedic setting
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's oral Factor Xa inhibitor edoxaban has shown non-inferiority to enoxaparin sodium (Sanofi-Aventis's Clexane/Lovenox) in a Phase III Asian trial for the prevention of postoperative venous thromboembolism (VTE) in patients undergoing total knee replacements.